Home
News
Capivasertib (Truqap): delays in Phase 1b/3 CAPItello-290 trial evaluating capivasertib + CDK4/6i + fulvestrant in HR+/HER2- metastatic breast cancer

Capivasertib (Truqap): delays in Phase 1b/3 CAPItello-290 trial evaluating capivasertib + CDK4/6i + fulvestrant in HR+/HER2- metastatic breast cancer

16 febbraio 2024

Attenzione! Il presente contenuto è disponibile solo in lingua originale.

AstraZeneca delayed the Primary Complition Date and Sickle Cell Disease of the Phase 1b/3 CAPItello-290 trial evaluating capivasertib (Truqap; AKTi) + CDK4/6i + fulvestrant in 1L+ ET resistant HR+/HER2- mBC by 15mo and 9mo, respectfully.

Tags: Capivasertib fulvestrant HR+/HER2- 1L+ mBC

Come giudichi questo contenuto?

Utile Non utile

Grazie per il tuo feedback!

Capivasertib (Truqap): delays in Phase 1b/3 CAPItello-290 trial evaluating capivasertib + CDK4/6i + fulvestrant in HR+/HER2- metastatic breast cancer

Come giudichi questo contenuto?

AZ: Capivasertib plus Faslodex migliora significatamente la PSF vs Faslodex nello studio di fase III CAPItello-291 nel tumore alla mammella avanzato HR+

US - FDA Approves AZ’s Truqap (capivasertib) Plus Faslodex (fulvestrant) for Advanced HR+ HER2- Breast Cancer

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Intercept announced receipt of a Complete Response Letter (CRL) from FDA for its Ocaliva

AstraZeneca and Daiichi Sankyo announced the voluntary withdrawal of the US application of Dato-DXd (TROP2 ADC) for 2L+ locally advanced or metastatic non-squamous (Nsq) lung cancer (NSCLC)